Lipella Pharmaceuticals Inc (LIPO)

Apr 23, 2025

Analytical Overview: Lipella Pharmaceuticals Inc (LIPO)’s Ratios Tell a Financial Story - DWinneX

Apr 23, 2025

Apr 23, 2025

Lipella Pharmaceuticals Abstract on Oral Lichen Planus - GlobeNewswire

Apr 23, 2025

Apr 23, 2025

Clinical Data: New Treatment Breakthrough for Oral Lichen PlanusPhase 2a Trial Shows Remarkable Improvement - Stock Titan

Apr 23, 2025

Apr 22, 2025

LIPO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Apr 22, 2025

Apr 22, 2025

LIPO stock’s current quarter earnings estimates: What analysts predict? - uspostnews.com

Apr 22, 2025

Apr 22, 2025

Lipella Reports Positive Results from Second Cohort in LP-310 Phase 2a Trial for Oral Lichen Planus - Reuters

Apr 22, 2025

Apr 22, 2025

Lipella Pharmaceuticals announces results from second cohort of LP-310 trial - TipRanks

Apr 22, 2025

Apr 22, 2025

Lipella Reports Positive Phase 2a Results from Second - GlobeNewswire

Apr 22, 2025

Apr 22, 2025

Clinical Trial Breakthrough: New Oral Lichen Planus Treatment Shows 65% Pain Reduction, Multiple Endpoint Success - Stock Titan

Apr 22, 2025

Apr 17, 2025

Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis - MarketBeat

Apr 17, 2025

Apr 14, 2025

Lipella Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Canada

Apr 14, 2025

Apr 14, 2025

Lipella Pharmaceuticals regains Nasdaq compliance - Investing.com Australia

Apr 14, 2025

Apr 10, 2025

Lipella Pharmaceuticals expands preferred stock class - Investing.com Australia

Apr 10, 2025

Apr 09, 2025

Lipella Pharmaceuticals stock hits 52-week low at $2 By Investing.com - Investing.com Canada

Apr 09, 2025

Apr 09, 2025

Lipella Pharmaceuticals expands preferred stock class By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 09, 2025

Lipella Pharmaceuticals stock hits 52-week low at $2 - Investing.com

Apr 09, 2025

Apr 08, 2025

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus - The Manila Times

Apr 08, 2025

Apr 08, 2025

Clinical Trial Success: Lipella's Novel OLP Treatment Shows Encouraging Results in Phase 2a Study - Stock Titan

Apr 08, 2025

Apr 02, 2025

Virtu Financial LLC Acquires Shares of 13,310 Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) - Defense World

Apr 02, 2025

Mar 31, 2025

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast - The Globe and Mail

Mar 31, 2025

Mar 31, 2025

Clinical Trial Success: Lipella's 40-Year Veteran Shares Breakthrough Journey in Exclusive Interview - Stock Titan

Mar 31, 2025

Mar 28, 2025

Tariffs and Tech Troubles Weigh on Markets - The Globe and Mail

Mar 28, 2025

Mar 28, 2025

Lipella Pharmaceuticals Inc. (LIPO) reports earnings - Quartz

Mar 28, 2025

Mar 28, 2025

LIPELLA PHARMACEUTICALS INC. SEC 10-K Report - TradingView

Mar 28, 2025

Mar 26, 2025

Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail

Mar 26, 2025

Mar 13, 2025

Spartan Capital Securities, LLC Proudly Serves as the Sole Agent in Lipella Pharmaceuticals Inc. - Ukraine Business Journal

Mar 13, 2025

Mar 08, 2025

Spartan Capital Securities, LLC Announces Key February Transactions - The Manila Times

Mar 08, 2025

Mar 07, 2025

Spartan Capital Securities, LLC Announces Key February Transactions - GlobeNewswire Inc.

Mar 07, 2025

Mar 07, 2025

Lipella Pharmaceuticals stock hits 52-week low at $2.21 - Investing.com India

Mar 07, 2025

Mar 04, 2025

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement - The Manila Times

Mar 04, 2025

Mar 04, 2025

Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire

Mar 04, 2025

Mar 04, 2025

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement - Yahoo Finance

Mar 04, 2025

Mar 02, 2025

Lipella Pharmaceuticals (LIPO) Expected to Announce Earnings on Tuesday - Defense World

Mar 02, 2025

Mar 01, 2025

FDA approves Lipella's oral treatment access program - MSN

Mar 01, 2025

Feb 24, 2025

Lipella Pharmaceuticals modifies agreement with Spartan Capital By Investing.com - Investing.com South Africa

Feb 24, 2025

Feb 24, 2025

Lipella Pharmaceuticals modifies agreement with Spartan Capital - Investing.com

Feb 24, 2025

Feb 21, 2025

With New Data, Lipella Plots 2025 Milestones For Oral Rinse Tacrolimus - News & Insights

Feb 21, 2025

Feb 17, 2025

Analyzing Lipella Pharmaceuticals (NASDAQ:LIPO) and IDEAYA Biosciences (NASDAQ:IDYA) - Defense World

Feb 17, 2025

Feb 13, 2025

Lipella Pharmaceuticals Gains Buy Rating from Jason McCarthy Following Positive Phase 2a Results for LP-310 - TipRanks

Feb 13, 2025

Feb 13, 2025

3 Penny Stocks to Watch Now, 2/13/25 - TipRanks

Feb 13, 2025

Feb 13, 2025

Lipella Pharmaceuticals Announces Positive Phase 2a Results for LP-310 in Oral Lichen Planus Treatment - Defense World

Feb 13, 2025

Feb 11, 2025

Biotech Rips On Topline Analysis - The Globe and Mail

Feb 11, 2025

Feb 11, 2025

Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes - AOL.com

Feb 11, 2025

Feb 11, 2025

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus - GlobeNewswire

Feb 11, 2025

Feb 11, 2025

Lipella Pharmaceuticals Shares Rise After Positive Phase 2a Trial Results for Oral Lichen Planus Treatment - Marketscreener.com

Feb 11, 2025

Feb 11, 2025

Stock market news: Firefly Neuroscience +214.56%, Dominari Holdings +37.66% among top gainers during midday trading - Business Upturn

Feb 11, 2025

Feb 11, 2025

Stock market today: Firefly Neuroscience +60.32%, Dominari Holdings +36.36% among top gainers in early trading - Business Upturn

Feb 11, 2025